{"protocolSection":{"identificationModule":{"nctId":"NCT06705140","orgStudyIdInfo":{"id":"VAD00015"},"secondaryIdInfos":[{"id":"2023-509536-26","type":"REGISTRY","domain":"CTIS"},{"id":"U1111-1298-7338","type":"REGISTRY","domain":"WHO ICTRP"},{"id":"2023","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2023"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers","officialTitle":"A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL)","acronym":"OPAL"},"statusModule":{"statusVerifiedDate":"2026-07","overallStatus":"TERMINATED","whyStopped":"Sponsor decision","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-11-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-06-11","type":"ACTUAL"},"completionDateStruct":{"date":"2025-06-11","type":"ACTUAL"},"studyFirstSubmitDate":"2024-11-22","studyFirstSubmitQcDate":"2024-11-22","studyFirstPostDateStruct":{"date":"2024-11-26","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-06-11","resultsFirstSubmitQcDate":"2026-07-30","resultsFirstPostDateStruct":{"date":"2026-08-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-07-30","lastUpdatePostDateStruct":{"date":"2026-08-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study was a Phase III, parallel group, randomized, observer blind, placebo controlled, multi-national, multi-center, multi-arm study conducted in 42 healthy children enrolled at 6 months to \\<22 months of age. The purpose of the study was to evaluate the non-inferiority of the immune response of the lower dose (LD) when compared to the standard dose (SD) respiratory syncytial virus infant and toddler (RSVt) vaccine and the safety of the LD, SD and high dose (HD) vaccine in preterm born children and of the HD vaccine in full term born children administered by intranasal route and compared to placebo.","detailedDescription":"The study duration was approximately 8 months for each participant, including the 6 months safety follow-up phone call after the second study intervention administration."},"conditionsModule":{"conditions":["RSV Immunisation","Healthy Volunteers"],"keywords":["RSV","RSVt (RSV toddler and Infant) Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","maskingDescription":"* Blinding for vaccine group assignment: participants, parents or legally acceptable representatives (LARs), outcome assessors, investigators, laboratory personnel, Sponsor study staff\n* No blinding for study staff who prepare and administer the study interventions","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":42,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1: Group 1- (SD RSVt vaccine)","type":"EXPERIMENTAL","description":"Participants received 2 intranasal administrations of SD RSVt vaccine","interventionNames":["Biological: Standard Dose (SD) RSVt vaccine"]},{"label":"Cohort 1: Group 2-Control","type":"PLACEBO_COMPARATOR","description":"Participants received 2 intranasal administrations of placebo","interventionNames":["Biological: Placebo"]},{"label":"Cohort 1: Group 3- (HD RSVt vaccine)","type":"EXPERIMENTAL","description":"Participants received 2 intranasal administrations of HD RSVt vaccine","interventionNames":["Biological: High Dose (HD) RSVt vaccine"]},{"label":"Cohort 1: Group 4-Control","type":"PLACEBO_COMPARATOR","description":"Participants received 2 intranasal administrations of placebo","interventionNames":["Biological: Placebo"]},{"label":"Cohort 2: Group 1- (LD RSVt vaccine)","type":"EXPERIMENTAL","description":"Participants received 2 intranasal administrations of LD RSVt vaccine","interventionNames":["Biological: Low Dose (LD) RSVt vaccine"]},{"label":"Cohort 2: Group 2- (SD RSVt vaccine)","type":"EXPERIMENTAL","description":"Participants received 2 intranasal administrations of SD RSVt vaccine","interventionNames":["Biological: Standard Dose (SD) RSVt vaccine"]},{"label":"Cohort 2: Group 3- (HD RSVt vaccine","type":"EXPERIMENTAL","description":"Participants received 2 intranasal administrations of HD RSVt vaccine","interventionNames":["Biological: High Dose (HD) RSVt vaccine"]},{"label":"Cohort 2: Group 4-Control","type":"PLACEBO_COMPARATOR","description":"Participants received 2 intranasal administrations of placebo","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Low Dose (LD) RSVt vaccine","description":"Pharmaceutical form:\n\nLiquid for nasal spray\n\nRoute of administration: Intranasal","armGroupLabels":["Cohort 2: Group 1- (LD RSVt vaccine)"],"otherNames":["534"]},{"type":"BIOLOGICAL","name":"Standard Dose (SD) RSVt vaccine","description":"Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal","armGroupLabels":["Cohort 1: Group 1- (SD RSVt vaccine)","Cohort 2: Group 2- (SD RSVt vaccine)"],"otherNames":["534"]},{"type":"BIOLOGICAL","name":"High Dose (HD) RSVt vaccine","description":"Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal","armGroupLabels":["Cohort 1: Group 3- (HD RSVt vaccine)","Cohort 2: Group 3- (HD RSVt vaccine"],"otherNames":["534"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal","armGroupLabels":["Cohort 1: Group 2-Control","Cohort 1: Group 4-Control","Cohort 2: Group 4-Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cohort 2: Geometric Mean Titers (GMT) of RSV A Serum Neutralizing Antibodies at Day 85 (Post-Dose 2)","description":"Serum samples were planned to be collected at specified timepoints for immunogenicity assessments. RSV A serum neutralizing antibody titers were planned to be determined using a validated plaque reduction neutralization test (PRNT).","timeFrame":"Day 85 (28 days post-vaccination 2)"},{"measure":"Cohort 2: Geometric Mean Titers of RSV B Serum Neutralizing Antibodies at Day 85 (Post-Dose 2)","description":"Serum samples were planned to be collected at specified timepoints for immunogenicity assessments. RSV B serum neutralizing antibody titers were planned to be determined using a validated PRNT.","timeFrame":"Day 85 (28 days post-vaccination 2)"},{"measure":"Cohorts 1 and 2: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after each vaccination and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs.","timeFrame":"Up to 30 minutes after each vaccination (post-dose on Day 1)"},{"measure":"Cohorts 1 and 2: Number of Participants With Solicited Administration Site Reactions","description":"A solicited injection/administration site reactions were adverse reactions (AR) at and around the injection/administration site of the study vaccine observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF and considered as related to the study vaccine administered.","timeFrame":"Up to 21 days after each vaccination (post-dose on Day 1)"},{"measure":"Cohorts 1 and 2: Number of Participants With Solicited Systemic Reactions","description":"A solicited reaction was an expected AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF and considered as related to the study vaccine administered.","timeFrame":"Up to 21 days after each vaccination (post-dose on Day 1)"},{"measure":"Cohorts 1 and 2: Number of Participants With Unsolicited Adverse Events","description":"An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.","timeFrame":"Up to 28 days after each vaccination (post-dose on Day 1)"},{"measure":"Cohorts 1 and 2: Number of Participants With Medically Attended Adverse Events (MAAEs)","description":"An MAAE was defined as a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department.","timeFrame":"From first dose of study vaccine administration (Day 1) to 198 days"},{"measure":"Cohorts 1 and 2: Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE was defined as any AE that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was other medically important event.","timeFrame":"From first dose of study vaccine administration (Day 1) to 198 days"},{"measure":"Cohorts 1 and 2: Number of Participants With Adverse Events of Special Interest (AESIs)","description":"An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's study vaccine or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. Acute wheeze and anaphylaxis were collected as AESI.","timeFrame":"From first dose of study vaccine administration (Day 1) to 198 days"}],"secondaryOutcomes":[{"measure":"Cohort 1: Geometric Mean Titers of RSV A and B Serum Neutralizing Antibodies at Baseline (Day 1) and Day 85","description":"Serum samples were planned to be collected at specified timepoints for immunogenicity assessments. RSV A and RSV B serum neutralizing antibody titers were planned to be determined using a validated PRNT.","timeFrame":"Baseline (Day 1) and Day 85"},{"measure":"Cohorts 1 and 2: Mean Titers of RSV Serum Anti-F Immunoglobulin (Ig) A and IgG Antibodies at Baseline (Day 1) and Day 85","description":"Serum samples were collected at specified timepoints for immunogenicity assessments. Antibodies to RSV F antigen were measured using the anti-RSV serum anti-F IgA and IgG using electrochemiluminescence method. Log10 titer values are reported.","timeFrame":"Baseline (Day 1) and Day 85"},{"measure":"Cohorts 1 and 2: Percentage of Participants With Quantified Shedding >=3.37 Lower Limit of Quantitation (LLOQ)","description":"Nasal swabs were collected to assess shedding of the attenuated RSV vaccine strain at specified timepoints. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay was developed to detect and quantify RSV ΔNS2 candidate in nasal swab samples. Percentages rounded off to tenth decimal place.","timeFrame":"Day 8 and Day 64"},{"measure":"Cohorts 1 and 2: Percentage of Participants With Detectable Shedding >=2.08 Limit of Detection","description":"Nasal swabs were collected to assess shedding of the attenuated RSV vaccine strain at specified timepoints. qRT-PCR assay was developed to detect and quantify RSV ΔNS2 candidate in nasal swab samples. Percentages rounded off to tenth decimal place.","timeFrame":"Day 8 and Day 64"},{"measure":"Cohorts 1 and 2: Titer of Vaccine Virus Shedding in Participants Detected in Nasal Samples Quantified by Quantitative Real Time-Polymerase Chain Reaction","description":"Nasal swabs were collected to assess shedding of the attenuated RSV vaccine strain at specified timepoints. qRT-PCR assay was developed to detect and quantify RSV ΔNS2 candidate in nasal swab samples. Quantified virus shedding was defined as vaccine virus shedding \\>=lower limit of quantification (LLOQ=3.37 log10 copies/mL).","timeFrame":"Day 8 and Day 64"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 6 months to \\< 22 months on the day of inclusion (means from the day of the 6-month birthday to the day before the 22-month birthday. The second vaccine administration was administered before the study participant has turned 24 months of age).\n* Participants who were healthy as determined by medical evaluation including medical history.\n* For Cohort 1 and Cohort 2 (contingent upon satisfactory safety profile of the RSVt vaccine in Cohort 1):\n\n  --Participant born 28 through 36 weeks of gestation and medically stable as assessed by the investigator, based on the following definition: \"Medically stable\" refers to the condition of premature infants who do not require significant medical support or ongoing management for debilitating disease and who have demonstrated a clinical course of sustained recovery by the time they receive the first dose of study intervention.\n* For Cohort 2:\n\n  * Participant born at full term of pregnancy (≥ 37 weeks of gestation).\n\nExclusion Criteria:\n\nParticipants were excluded from the study if any of the following criteria apply:\n\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances.\n\nChronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.\n\n* History of medically diagnosed wheezing. Children with a history of recurrent wheezing will be excluded. Children with a previous single episode of wheezing may be included if that episode of wheezing was not associated with hospitalization or if does not have a family history of wheezing.\n* Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.\n* Probable or confirmed ongoing case of viral respiratory infection (including COVID-19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.\n* Member of a household that contains an immunocompromised individual, including, but not limited to:\n\n  * a person who is HIV infected\n  * a person who has received chemotherapy within the 12 months prior to study enrollment\n  * a person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents\n  * a person living with a solid organ or bone marrow transplant\n* Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion.\n* Participant's biological mother's previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding.\n* Receipt or planned receipt of any of the following vaccines prior to enrollment or after the first study intervention administration:\n\n  * Any other intranasal live attenuated vaccine within the 28 days prior to and after Dose 1 study administration\n  * Unless given on the day of the first study intervention administration, any other injectable live attenuated vaccines within the 28 days prior to and after. Concomitant receipt on the day of the first study intervention administration is allowed\n* Planned receipt of any monoclonal antibody for RSV (such as Nirsevimab or Palivizumab) for the duration of the study.\n* Previous receipt of an investigational RSV vaccine or receiving any anti-RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment. Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration.\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months\n* Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment\n* Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure\n\nNote: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"21 Months","stdAges":["CHILD"]},"contactsLocationsModule":{"locations":[{"facility":"Investigational Site Number : 3400002","city":"San Pedro Sula","country":"Honduras","geoPoint":{"lat":15.50585,"lon":-88.02588}},{"facility":"Investigational Site Number : 3400001","city":"Tegucigalpa","zip":"11101","country":"Honduras","geoPoint":{"lat":14.0818,"lon":-87.20681}},{"facility":"Investigational Site Number : 3400003","city":"Tegucigalpa","zip":"11101","country":"Honduras","geoPoint":{"lat":14.0818,"lon":-87.20681}}]},"referencesModule":{"seeAlsoLinks":[{"label":"VAD00015 Plain Language Results Summary","url":"https://www.trialsummaries.com/Study/StudyDetails?id=26337&tenant=MT_SNY_9011"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Cohort 1: Groups 1 and 2 and Cohort 2 initiated enrollment at the same time. However, due to the early study termination (29 days following the first vaccination) as per sponsor's decision (no safety concerns), enrollment in Cohort 1 Groups 3 and 4 did not occur. No participants received the second vaccination.","recruitmentDetails":"Study was conducted at 1 center in a single country from 25 November 2024 to 13 December 2024. 42 healthy infants/toddlers aged 6 to\\<22 months were randomized to 2 cohorts: preterm born children(Cohort1:randomized to receive either placebo or standard dose of live-attenuated respiratory syncytial virus delta\\[Δ\\] non-structural \\[NS\\]2/Δ1313/I1314L vaccine \\[RSVt vaccine\\]) and full term born children (Cohort2:randomized to receive either low dose, standard dose or high dose RSVt vaccine or placebo).","groups":[{"id":"FG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 milliliter (mL) (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"FG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"FG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"FG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"FG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"FG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"5"}]},{"type":"COMPLETED","comment":"Participants who completed 6-month follow-up period, but did not complete study intervention period, due early termination of the study (29 days following the first vaccination).","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Randomized analysis set consisted of participants for whom a study vaccine group had been allocated.","groups":[{"id":"BG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"BG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"BG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"BG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"BG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"BG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"42"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16.5","spread":"0.707"},{"groupId":"BG001","value":"14.0","spread":"5.20"},{"groupId":"BG002","value":"13.0","spread":"3.71"},{"groupId":"BG003","value":"10.9","spread":"2.69"},{"groupId":"BG004","value":"11.8","spread":"3.38"},{"groupId":"BG005","value":"10.0","spread":"2.12"},{"groupId":"BG006","value":"12.0","spread":"3.43"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"17"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"25"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"42"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Cohort 2: Geometric Mean Titers (GMT) of RSV A Serum Neutralizing Antibodies at Day 85 (Post-Dose 2)","description":"Serum samples were planned to be collected at specified timepoints for immunogenicity assessments. RSV A serum neutralizing antibody titers were planned to be determined using a validated plaque reduction neutralization test (PRNT).","populationDescription":"As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination. As pre-specified in the statistical analysis plan (SAP), PRNT testing was not conducted, as it was not scientifically justified given the early termination due to the clinical hold. Accordingly, only RSV serum anti-F IgA and anti-F IgG antibody titers at Day 1 are presented, consistent with the pre-specified SAP analyses.","reportingStatus":"POSTED","timeFrame":"Day 85 (28 days post-vaccination 2)","groups":[{"id":"OG000","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"type":"PRIMARY","title":"Cohort 2: Geometric Mean Titers of RSV B Serum Neutralizing Antibodies at Day 85 (Post-Dose 2)","description":"Serum samples were planned to be collected at specified timepoints for immunogenicity assessments. RSV B serum neutralizing antibody titers were planned to be determined using a validated PRNT.","populationDescription":"As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination. As pre-specified in the SAP, PRNT testing was not conducted, as it was not scientifically justified given the early termination due to the clinical hold. Accordingly, only RSV serum anti-F IgA and anti-F IgG antibody titers at Day 1 are presented, consistent with the pre-specified SAP analyses.","reportingStatus":"POSTED","timeFrame":"Day 85 (28 days post-vaccination 2)","groups":[{"id":"OG000","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after each vaccination and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs.","populationDescription":"Safety analysis set (SafAS) consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 30 minutes after each vaccination (post-dose on Day 1)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Solicited Administration Site Reactions","description":"A solicited injection/administration site reactions were adverse reactions (AR) at and around the injection/administration site of the study vaccine observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF and considered as related to the study vaccine administered.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 21 days after each vaccination (post-dose on Day 1)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Solicited Systemic Reactions","description":"A solicited reaction was an expected AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF and considered as related to the study vaccine administered.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 21 days after each vaccination (post-dose on Day 1)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"4"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Unsolicited Adverse Events","description":"An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days after each vaccination (post-dose on Day 1)","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Medically Attended Adverse Events (MAAEs)","description":"An MAAE was defined as a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study vaccine administration (Day 1) to 198 days","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE was defined as any AE that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was other medically important event.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study vaccine administration (Day 1) to 198 days","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Cohorts 1 and 2: Number of Participants With Adverse Events of Special Interest (AESIs)","description":"An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's study vaccine or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was appropriate. Acute wheeze and anaphylaxis were collected as AESI.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose of study vaccine administration (Day 1) to 198 days","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cohort 1: Geometric Mean Titers of RSV A and B Serum Neutralizing Antibodies at Baseline (Day 1) and Day 85","description":"Serum samples were planned to be collected at specified timepoints for immunogenicity assessments. RSV A and RSV B serum neutralizing antibody titers were planned to be determined using a validated PRNT.","populationDescription":"As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination. As pre-specified in the SAP, PRNT testing was not conducted, as it was not scientifically justified given the early termination due to the clinical hold. Accordingly, only RSV serum anti-F IgA and anti-F IgG antibody titers at Day 1 are presented, consistent with the pre-specified SAP analyses.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and Day 85","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Cohorts 1 and 2: Mean Titers of RSV Serum Anti-F Immunoglobulin (Ig) A and IgG Antibodies at Baseline (Day 1) and Day 85","description":"Serum samples were collected at specified timepoints for immunogenicity assessments. Antibodies to RSV F antigen were measured using the anti-RSV serum anti-F IgA and IgG using electrochemiluminescence method. Log10 titer values are reported.","populationDescription":"Full analysis set (FAS) consisted of subset of randomized participants who received at least 1 administration of the study vaccine. Participants did not receive second dose of vaccination as study was terminated. Hence, no samples collected on Day 85.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"titer","timeFrame":"Baseline (Day 1) and Day 85","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"title":"Baseline (Day 1): IgA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"0.622"},{"groupId":"OG001","value":"1.45","spread":"1.52"},{"groupId":"OG002","value":"1.35","spread":"0.881"},{"groupId":"OG003","value":"0.502","spread":"0.364"},{"groupId":"OG004","value":"1.56","spread":"0.953"},{"groupId":"OG005","value":"0.921","spread":"0.863"}]}]},{"title":"Day 85: IgA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Baseline (Day 1): IgG","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.709","spread":"1.14"},{"groupId":"OG001","value":"1.79","spread":"1.87"},{"groupId":"OG002","value":"2.55","spread":"0.878"},{"groupId":"OG003","value":"0.935","spread":"0.798"},{"groupId":"OG004","value":"2.55","spread":"0.911"},{"groupId":"OG005","value":"1.57","spread":"1.22"}]}]},{"title":"Day 85: IgG","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cohorts 1 and 2: Percentage of Participants With Quantified Shedding >=3.37 Lower Limit of Quantitation (LLOQ)","description":"Nasal swabs were collected to assess shedding of the attenuated RSV vaccine strain at specified timepoints. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay was developed to detect and quantify RSV ΔNS2 candidate in nasal swab samples. Percentages rounded off to tenth decimal place.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination. Hence, no samples collected on Day 64.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 8 and Day 64","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"84.2"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"70.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"30.8"},{"groupId":"OG003","value":"40.0","lowerLimit":"12.2","upperLimit":"73.8"},{"groupId":"OG004","value":"25.0","lowerLimit":"5.5","upperLimit":"57.2"},{"groupId":"OG005","value":"0","lowerLimit":"0","upperLimit":"52.2"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cohorts 1 and 2: Percentage of Participants With Detectable Shedding >=2.08 Limit of Detection","description":"Nasal swabs were collected to assess shedding of the attenuated RSV vaccine strain at specified timepoints. qRT-PCR assay was developed to detect and quantify RSV ΔNS2 candidate in nasal swab samples. Percentages rounded off to tenth decimal place.","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination. Hence, no samples collected on Day 64.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 8 and Day 64","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"84.2"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"70.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"30.8"},{"groupId":"OG003","value":"50.0","lowerLimit":"18.7","upperLimit":"81.3"},{"groupId":"OG004","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"},{"groupId":"OG005","value":"0","lowerLimit":"0","upperLimit":"52.2"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Cohorts 1 and 2: Titer of Vaccine Virus Shedding in Participants Detected in Nasal Samples Quantified by Quantitative Real Time-Polymerase Chain Reaction","description":"Nasal swabs were collected to assess shedding of the attenuated RSV vaccine strain at specified timepoints. qRT-PCR assay was developed to detect and quantify RSV ΔNS2 candidate in nasal swab samples. Quantified virus shedding was defined as vaccine virus shedding \\>=lower limit of quantification (LLOQ=3.37 log10 copies/mL).","populationDescription":"SafAS consisted of participants who had received at least 1 administration of the study vaccine. As study was terminated 29 days after first vaccination, participants did not receive second dose of vaccination. Hence, no samples collected on Day 64. Only participants with quantified vaccine virus shedding (\\>= 3.37 LLOQ) have been reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"log10 copies/mL","timeFrame":"Day 8 and Day 64","groups":[{"id":"OG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."},{"id":"OG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG003","value":"5.20","spread":"1.02"},{"groupId":"OG004","value":"4.91","spread":"1.33"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events and death were collected from first dose of study vaccine administration (Day 1) up to end of follow-up per participant, 198 days.","description":"Analysis was performed on the SafAS.","eventGroups":[{"id":"EG000","title":"Cohort 1: Group 1: Standard Dose RSVt","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":0,"otherNumAtRisk":2},{"id":"EG001","title":"Cohort 1: Group 2: Placebo","description":"Participants born after a gestation period of 28 through 36 weeks (pre-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG002","title":"Cohort 2: Group 1: Low Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received low dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":6,"otherNumAtRisk":10},{"id":"EG003","title":"Cohort 2: Group 2: Standard Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received standard dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":9,"otherNumAtRisk":10},{"id":"EG004","title":"Cohort 2: Group 3: High Dose RSVt","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received high dose of RSVt vaccine 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":7,"otherNumAtRisk":12},{"id":"EG005","title":"Cohort 2: Group 4: Placebo","description":"Participants born after a gestation period of \\>=37 weeks (full-term) received placebo 0.2 mL (0.1 mL per nostril) as intranasal administration on Day 1.","deathsNumAffected":0,"deathsNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"otherNumAffected":4,"otherNumAtRisk":5}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":5}]}],"otherEvents":[{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":5}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":10},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":5}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":10},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":10},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":5}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Crying","organSystem":"General disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":10},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":5}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":5}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra 28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":5}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The study was terminated early as per sponsor's decision (no safety concerns)."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Trial Transparency Team","organization":"Sanofi Pasteur","email":"Contact-US@sanofi.com","phone":"800-633-1610","phoneExt":"6#"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2025-09-24","uploadDate":"2026-06-11T12:54","filename":"Prot_000.pdf","size":1054391},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2026-02-09","uploadDate":"2026-06-11T12:54","filename":"SAP_001.pdf","size":4092163}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Dominican Republic"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-07-08","type":"ACTUAL"}}}},"interventionBrowseModule":{"meshes":[{"id":"C061529","term":"YM 534"}]}},"hasResults":true}